Literature DB >> 26498960

Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy.

Johannes Krämer1,2, Peter Nordbeck1,3, Stefan Störk1,3, Christian Ritter1,3, Georg Ertl1,3, Christoph Wanner1,3, Frank Weidemann4,5.   

Abstract

BACKGROUND: In Fabry cardiomyopathy, little is known about the interaction between its key feature of myocardial replacement fibrosis and changes in resting, Holter, and exercise electrocardiography (-ECG). METHODS AND
RESULTS: Resting ECG, 24-h Holter ECG, and exercise ECG were performed in 95 patients (50 women) with Fabry disease, staged using cardiac magnetic resonance imaging to measure left ventricular fibrosis. With resting ECG, T alterations were seen in patients with cardiac fibrosis, while time intervals and rhythm were unchanged (except for a longer QRS duration in patients with severe fibrosis). All patients with severe fibrosis showed T inversion, ST alteration, or both. With Holter ECG, maximum and minimum heart rate did not differ with fibrosis severity. Patients without fibrotic tissue showed less ventricular premature beats (VPB) (median 5/24 h) compared to those with mild (median 11/24 h) or severe fibrosis (median 115/24 h; P < 0.05, respectively). Fibrosis was a strong predictor of VPB burden (r 2 = 0.5; P < 0.001). During exercise, patients with severe fibrosis had the least increase in systolic blood pressure (sBP) (47 ± 22 mmHg vs. 62 ± 25 mmHg, P < 0.05) and the lowest maximum heart rate (113 ± 18/min; P < 0.05). Patients with mild fibrosis had a high sBP during exercise (198 ± 37 mmHg; P < 0.05). Decreased diastolic blood pressure (>10 mmHg) occurred in some patients with no (3/41) or mild fibrosis (3/34) but not in patients with severe fibrosis (0/20; P < 0.01).
CONCLUSIONS: Our data suggest that cardiac replacement fibrosis is responsible for repolarization abnormalities on resting ECG and increased VPB with Holter ECG. During exercise ECG, advanced cardiomyopathy is characterized by chronotropic incompetence with limitations on blood pressure and heart rate increase.

Entities:  

Year:  2015        PMID: 26498960      PMCID: PMC5059213          DOI: 10.1007/8904_2015_502

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  19 in total

1.  Cardiopulmonary involvement in Fabry's disease.

Authors:  Juha W Koskenvuo; Ilkka M Kantola; Pirjo Nuutila; Juhani Knuuti; Riitta Parkkola; Ilkka Mononen; Saija Hurme; Riikka Kalliokoski; Jorma S Viikari; Maria Wendelin-Saarenhovi; Tuomas O Kiviniemi; Jaakko J Hartiala
Journal:  Acta Cardiol       Date:  2010-04       Impact factor: 1.718

2.  The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

Authors:  James C Moon; Mary Sheppard; Emma Reed; Phillip Lee; Perry M Elliott; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

3.  Electrocardiographic changes in early recognition of Fabry disease.

Authors:  Mehdi Namdar; Jan Steffel; Mile Vidovic; Corinna B Brunckhorst; Johannes Holzmeister; Thomas F Lüscher; Rolf Jenni; Firat Duru
Journal:  Heart       Date:  2011-01-26       Impact factor: 5.994

4.  PQ interval in patients with Fabry disease.

Authors:  Mehdi Namdar; Christoph Kampmann; Jan Steffel; Daniel Walder; Johannes Holzmeister; Thomas Felix Lüscher; Rolf Jenni; Firat Duru
Journal:  Am J Cardiol       Date:  2010-03-01       Impact factor: 2.778

5.  Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Authors:  Jaymin S Shah; Derralynn A Hughes; Bhavesh Sachdev; Maite Tome; Deirdre Ward; Philip Lee; Atul B Mehta; Perry M Elliott
Journal:  Am J Cardiol       Date:  2005-09-15       Impact factor: 2.778

6.  Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.

Authors:  C Kampmann; C M Wiethoff; C Martin; A Wenzel; R Kampmann; C Whybra; E Miebach; M Beck
Journal:  Acta Paediatr Suppl       Date:  2002

Review 7.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

Review 8.  Cardiac challenges in patients with Fabry disease.

Authors:  F Weidemann; A Linhart; L Monserrat; J Strotmann
Journal:  Int J Cardiol       Date:  2009-08-31       Impact factor: 4.164

9.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

10.  Prevalence of symptoms in female Fabry disease patients: a case-control survey.

Authors:  Machtelt G Bouwman; Saskia M Rombach; Erica Schenk; Annelies Sweeb; Frits A Wijburg; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2012-03-20       Impact factor: 4.982

View more
  1 in total

1.  Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study.

Authors:  Lu Zhao Di; Maxime Pichette; Réginald Nadeau; Daniel G Bichet; Frédéric Poulin
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.